Investigating the molecular mechanism of the BAT antiviral factor RTP4
Active Project Grant Awarded Last action
- Award ID
- F31AI200260
- Recipient
-
The University Of Texas Southwestern Medical Center UEI YZJ6DKPM4W63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $82,896
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 0% complete
- Originally
- Place of performance
- Dallas, TX 75390, USA
Award details come from USAspending.gov.
Description
- Abstract
- Bats harbor numerous zoonotic viruses yet rarely develop disease, indicating they may have unique antiviral defenses. Receptor-transporting protein 4 (RTP4) is an interferon-induced effector protein that inhibits flavivirus replication. BAT RTP4 is markedly more potent than the human RTP4, but the underlying mechanism remains undefined. Preliminary data suggests BAT RTP4 binds flavivirus RNA with high affinity and competes with the viral replicase. This proposal will test the hypothesis that preferential binding of RTP4 to a conserved RNA motif blocks genome amplification. Aim 1 will delineate molecular determinants of RTP4-RNA recognition by quantifying binding affinities of BAT and human RTP4 variants for viral RNA and by solving the structure of BAT RTP4 in complex with its target. Aim 2 will define functional consequences of RTP4-RNA interaction by measuring how RTP4 influences replicase binding to the viral promoter and alters helicase and polymerase activities. The research plan combines virology, genetics, and cell biology with intensive new training for the applicant on biochemical approaches. The training plan also emphasizes scholarship to disseminate findings, mentorship, and professional development. Supported by a comprehensive mentoring team, resources, facilities, and a rich scientific environment at UT southwestern medical center, the applicant's research is poised to make fundamental contributions to antiviral immunity and provide a meaningful training opportunity for a future career in science.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $41,448 | |
| Amendment | $0 | |
| Original award | $41,448 |
Quick answers
Who received award F31AI200260?
F31AI200260 was awarded to The University Of Texas Southwestern Medical Center by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 4, 2026.
How much is award F31AI200260 worth?
$82,896 has been obligated on F31AI200260.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award